Transition to ICD-10: Clear up confusion about 5010 and drug claims

Why This Topic Matters

Drug claims often involve formatting and reporting details that can vary between transaction standards and payer instructions. Understanding the general 5010 framework helps billing staff evaluate whether their current workflows, testing, and claim submission practices align with published guidance.

Article Sections

1. Questions about 4010 versus 5010 drug claims

   Introduces the billing concerns raised about drug claims during the transition to the newer claim standard. It frames the article around payer testing and common reporting questions.

2. National Drug Code reporting

   Summarizes guidance on how drug identifier information is handled in the 5010 claim environment. It focuses on the general reporting framework and payer references cited in the article.

3. Compound drugs

   Addresses how compound drug claims are discussed under the newer claim format. The section focuses on how multiple ingredients relate to claim structure at a broad level.

4. Epoetin

   Discusses a specific medication example used to clarify reporting questions involving multiple product sources. The section ties that example to the broader compound-drug discussion.

5. Oral anti-cancer drugs

   Covers billing questions for oral anti-cancer drugs and references to claim segments, payer handling, and related CMS guidance. It also notes where the article points readers for further official reference.